Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Net Income (2016 - 2022)

Edesa Biotech's Net Income history spans 10 years, with the latest figure at -$2.8 million for Q3 2022.

  • For Q3 2022, Net Income rose 23.66% year-over-year to -$2.8 million; the TTM value through Sep 2022 reached -$18.3 million, down 37.29%, while the annual FY2025 figure was -$7.2 million, 16.46% down from the prior year.
  • Net Income for Q3 2022 was -$2.8 million at Edesa Biotech, up from -$5.8 million in the prior quarter.
  • Across five years, Net Income topped out at -$364849.0 in Q4 2018 and bottomed at -$5.8 million in Q2 2022.
  • The 5-year median for Net Income is -$2.0 million (2020), against an average of -$2.6 million.
  • The largest annual shift saw Net Income soared 73.95% in 2018 before it crashed 199.94% in 2019.
  • A 5-year view of Net Income shows it stood at -$364849.0 in 2018, then plummeted by 199.94% to -$1.1 million in 2019, then crashed by 141.02% to -$2.6 million in 2020, then crashed by 95.46% to -$5.2 million in 2021, then soared by 45.42% to -$2.8 million in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Net Income are -$2.8 million (Q3 2022), -$5.8 million (Q2 2022), and -$4.6 million (Q1 2022).